Curie Oncology

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Gastric and oesophageal cancer2 trials
• Liver and biliary tract cancer2 trials
• Metastatic breast cancer2 trials
• Bladder cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Melanoma1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 35 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Completed4 trials
• Recruiting3 trials
• Active, not recruiting2 trials

Lead sponsor

• Arcus Biosciences, Inc.1 trial
• BioNTech SE1 trial
• Celcuity Inc1 trial
• Coherus Oncology, Inc.1 trial
• Hoffmann-La Roche1 trial
• and 4 more

Running trials

• Recruiting

  ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

  NCT07173751· Phase 3· BioNTech SE· Source

• Active, not recruiting

  A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma

  NCT06679985· Phase 2· Coherus Oncology, Inc.· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

  Contact: Toh Chee Keong

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· LeonaBio· Source

  Contact: Su-Mien Lynette Ngo

• Active, not recruiting

  Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

  NCT05501886· Phase 3· Celcuity Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

  NCT04785820· Phase 2· Hoffmann-La Roche· Source

• Completed

  Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

  NCT04723004· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

  NCT04262856· Phase 2· Arcus Biosciences, Inc.· Source

• Recruiting

  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  NCT04198766· Phase 1/2· Inhibrx Biosciences, Inc· Source

  Contact: Study Director - Inhibrx Biosciences, Inc